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A B S T R A C TObjective: To assess the cost-effectiveness of duloxetine in the treat-
ment of chronic low back pain (CLBP) from a US private payer
perspective. Methods: A cost-utility analysis was undertaken for
duloxetine and seven oral post–first-line comparators, including
nonsteroidal anti-inflammatory drugs (NSAIDs), weak and strong
opioids, and an anticonvulsant. We created a Markov model on the
basis of the National Institute for Health and Clinical Excellence
model documented in its 2008 osteoarthritis clinical guidelines.
Health states included treatment, death, and 12 states associated
with serious adverse events (AEs). We estimated treatment-specific
utilities by carrying out a meta-analysis of pain scores from CLBP
clinical trials and developing a transfer-to-utility equation using
duloxetine CLBP patient-level data. Probabilities of AEs were taken
from the National Institute for Health and Clinical Excellence model
or estimated from osteoarthritis clinical trials by using a novel
maximum-likelihood simulation technique. Costs were gathered from
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pondence to: Ronald C. Wielage, Medical DecisionCost and Utilization Project database, the literature, and, for a limited
number of inputs, expert opinion. The model performed one-way and
probabilistic sensitivity analyses and generated incremental cost-
effectiveness ratios (ICERs) and cost acceptability curves. Results: The
model estimated an ICER of $59,473 for duloxetine over naproxen.
ICERs under $30,000 were estimated for duloxetine over non-NSAIDs,
with duloxetine dominating all strong opioids. In subpopulations at a
higher risk of NSAID-related AEs, the ICER over naproxen was $33,105
or lower. Conclusions: Duloxetine appears to be a cost-effective
post–first-line treatment for CLBP compared with all but generic
NSAIDs. In subpopulations at risk of NSAID-related AEs, it is particu-
larly cost-effective.
Keywords: chronic low back pain, cost-effectiveness, cost-utility
analysis, duloxetine, pharmacoeconomic model.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Low back pain (LBP) is the second most common cause of
disability in the United States, exceeded only by arthritis and
rheumatism [1]. During a 3-month period, 28.1% of US adults
experience a day or more of LBP [2]. An estimated 70% to 80% of
the population will experience LBP in their lifetimes [3] of whom
10% will progress to chronic LBP (CLBP). Although studies esti-
mating the economic burden to the US economy have varied in
methodology, they agree that the cost of LBP is large: $12 to $90
billion is incurred annually in direct costs, with indirect costs
perhaps three times higher [4]. Few studies differentiate the cost
of CLBP versus nonchronic or acute LBP.
CLBP has been variously defined but typically is described as
LBP that is present longer than 3 months [5,6]. In North America,
the prevalence of CLBP is estimated at 9% to 10.2% and appears to
be increasing, up from 3.9% in 1992 [7,8]. Approximately 74.4% of
the CLBP population suffers moderate to severe pain [8]. CLBP is
often a mixed pain syndrome with nociceptive, neuropathic, and
hyperalgesic components [9].Few clinical trials of oral treatments for CLBP have been
conducted. A 2011 review of pharmacological treatments for
CLBP found only four studies of nonsteroidal anti-inflammatory
drugs (NSAIDs), five of antidepressants, and eight of opioids;
moreover, the review found that the quality of the evidence as of
publication was low [10]. A 2009 review of pharmacotherapy for
chronic pain reported no treatments with good-quality evidence
of substantial benefit in LBP [11].
Cost-effectiveness analyses (CEAs) have been recognized as a
pressing need [12]. Even so, few have been conducted [13]. The
National Institute for Health and Clinical Excellence (NICE)
reported that no economic models could be located for NSAIDs,
opioids, or antidepressants for its 2009 guideline for LBP [14].
Duloxetine, a selective serotonin and norepinephrine reup-
take inhibitor, has demonstrated analgesic effects in CLBP in
three 13-week randomized controlled trials (RCTs) [15–17]. Long-
term efficacy has been demonstrated in an open label extension
trial of 41 weeks [18]. A pooled analysis of duloxetine RCTs
completed through 2008 reported that most treatment emergent
adverse events (AEs) tended to be mild to moderate in severitySociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 3 4 – 3 4 4 335and transitory in nature [19]. In November 2010, the US Food and
Drug Administration approved duloxetine for chronic musculos-
keletal pain [20]. By using the relative wealth of data available for
duloxetine, we parameterized a pharmacoeconomic model to
compare the cost-effectiveness of duloxetine and seven oral
post–first-line comparators in CLBP treatment, including NSAIDs,
weak and strong opioids, and an anticonvulsant.Methods
The authors developed a semi-Markov model from a US private
payer perspective for oral treatments of CLBP in a post–first-line
(post-acetaminophen [APAP]) place in therapy. We modeled
duloxetine and comparators representing commonly used drug
classes in the US market: a nonselective NSAID and a COX-2
inhibitor, strong opioids, weak opioid/monoamine reuptake inhi-
bitors, an anticonvulsant as well as a combination product.
Specifically, the model included naproxen, celecoxib, oxycodone
extended release (oxycodone), tapentadol extended release
(tapentadol), tramadol immediate release (tramadol), pregabalin,
and oxycodone/APAP as comparators to duloxetine (Table 1).
CLBP and osteoarthritis (OA) are both chronic musculoskeletal
conditions that are commonly treated with NSAIDs and opioids.
In both conditions, these oral treatments are not disease modify-
ing, but provide symptomatic improvement in pain associated
with the condition. Therefore, in the absence of CEAs in CLBP, we
referenced the 2008 OA economic model published by NICE as a
framework. Appendix D of the NICE OA guidelines documents the
model, with additional documentation of treatment-specific
utilities in Appendix C [33]. The NICE LBP clinical guidance refers
to the OA guidelines concerning treatment with NSAIDs [14].
Model Overview
The model is a discrete-state, time-dependent semi-Markov
model with changing probabilities as the cohort ages. Treatment
efficacy, AE profile, and discontinuation as well as concomitant
proton pump inhibitor (PPI) usage are the clinical dimensions
modeled. Economic inputs include drug costs and medical
utilization for the management of AEs, titration, and disconti-
nuation. The model includes two types of AEs: persistent and
transient. Persistent AEs disrupt treatment, increase costs, and
have a permanent effect on mortality and health-related quality
of life (HRQoL). Transient AEs temporarily increase costs and
lower HRQoL but have no permanent effect. Treatment-specific
utilities represent treatment efficacy in the model. AE profiles are
modeled with 3-month probabilities of incurring persistent or
transient events. We modeled aging by using age-dependent
relative risks of persistent AEs, age-specific general population
utility weights, and increasing mortality. The model calculates
cycle-specific utilities from the interaction between utilities/
utility weights representing treatment efficacy, age, and AEs.
Model inputs are parameterized from the NICE model, meta-
analysis, the literature, and, for a small number of inputs, expert
opinion.
Structure
We used a lifetime time horizon with 3-month cycles to the
maximum length of treatment and annual cycles thereafter. This
allows the model to accumulate the long-term effects of NSAID-
related AEs. Health states include treatment, death, and 12
during- and post- persistent-AE states. In the treatment state,
the patient experiences the increased HRQoL due to treatment,
reductions to HRQoL due to transient AEs, and changes in HRQoL
due to discontinuation and switch to a post-discontinuation
basket of treatments (PDBT). The PDBT is composed of allcomparators weighted by market share (days prescribed). Costs
are incurred in the treatment state for treatment drugs, manage-
ment of transient AEs, and medical services related to titration
and discontinuation. Upon the end of the treatment period, the
portion of the cohort still receiving each comparator discontinues
and switches to the PDBT. In the base case, treatment is for the
lesser of 1 year, until discontinuation, or until occurrence of a
persistent AE and is followed by treatment from the PDBT
until death.
Patients transition to other health states upon death or any of
six persistent AEs. These health state transitions may take place
during the original treatment period or after switch to the PDBT.
The patient enters a 3-month during-AE health state followed by
a post-AE state in which the patient continues until death.
During these states, HRQoL, excess mortality, and cost are
assessed as appropriate to the AE. The age of the cohort during
each cycle determines the appropriate background mortality.
Figure 1 is a simplified depiction of the model structure.
Adverse Events
Persistent AEs include cardiovascular (CV) and gastrointestinal
(GI) AEs associated with NSAID treatment as well as fracture, an
AE associated with opioid and anticonvulsant comparators
(Table 2). Transient AEs included in the model occur at substan-
tially different rates among the comparators, potentially having
economic and HRQoL impacts (Table 3).
Transition Probabilities
We used the 3-month CV and GI AE probabilities from the NICE
model for naproxen and celecoxib, and assumed equivalence to
no treatment for other comparators [33]. The probabilities of
fracture were derived principally from odds ratios calculated by
Vestergaard and colleagues and applied to rates of fracture in the
general population [35,36,46,52,62–65]. We examined duloxetine
CLBP clinical trial reports for rates of fracture; fractures occurred
at or below the rates found in the control arms [34,66,67]. Age-
dependent relative risks from the literature were then applied to
these probabilities [46,57,58].
The age-dependent probability of background mortality at
each cycle is calculated from a US life table [68], while excess
mortality associated with each persistent AE was derived from a
variety of sources in the literature [33,46,51,53–56,69].
Transient AE and Discontinuation Probabilities
We conducted meta-analyses for most transient AEs and for
discontinuation by using CLBP RCTs for duloxetine and OA RCTs
for NSAIDs and opioids, as more OA RCTs were available. A 12-
week minimum duration of treatment was among the inclusion
criteria. Three-month probabilities of dyspepsia for naproxen and
celecoxib were taken from the NICE model, and were assumed
equivalent to no treatment for other comparators [33].
We used conventional techniques for the AE meta-analysis
when possible. A maximum-likelihood simulation technique was
used when an AE rate fell below the reporting threshold for one
or more RCTs of a treatment. This technique assumed that all
RCTs for that treatment experienced the AE rate within the same
binomial distribution truncated by the publication reporting
thresholds. In the case that no publications for a treatment
reported a rate for an AE, a rate was assumed equal to that of
another medication in the same class. AE rates for tapentadol
were taken from the Nucynta package insert.
A meta-analysis of discontinuation rates from the OA RCTs
above was used to calculate discontinuation probabilities in the
first 3-month cycle of treatment for NSAIDs and opioids. Data
were pooled from two RCTs in neuropathic pain for pregabalin
Table 1 – Treatment characteristics.
Comparator Duloxetine Celecoxib Naproxen Pregabalin Oxycodone/APAP Oxycodone ER Tapentadol ER Tramadol IR
Clinical
Dosing 60–120 mg 200 mg QD 500 mg BID 300 mg BID 7.5/325– 15/650 Q6h 10–30 mg BID 300–600 mg QD 200–300 mg QD
Utility 0.7541 0.7688 0.7688 0.7282y [21] 0.7628( 0.7628 0.7603 0.7587
Discon—initial 3 mo (%) 27.6 23.8y 30.0y 35.0 [22,23] 58.9( 58.9y 44.0 [24] 48.5y
Discon—subsequent 3 mo (%)99 1.9 4.7 5.7 4.5 13.3 13.3 8.3 25.4
PPI usage (%) 5.1 [25] 15.5 [26] 43.7 [27] 5.1 [25] 21.0 [25] 21.0 [25] 21.0 [25] 21.0 [25]
Share of PDT (%) [28] 5.0 9.2 17.1 8.6 19.2 6.0 1.0 33.9
Treatment costs ($)
Initial 3-mo drug cost [29,30] 576.41 371.09 162.41 439.83 154.55 589.04 1,229.27 262.63
Initial 3-mo physician cost99 [31,32] 167.50 0.00 0.00 192.84 184.06 287.65 169.95 153.82
Cost—subsequent 3 mo [29] 590.23 371.09 162.41 474.28 188.20 667.51 1,340.30 309.89
Discon drug cost [29,30] 0.00 0.00 0.00 94.62 27.57 190.34 632.28 44.01
Discon provider cost99 [31,32] 94.80 0.00 0.00 106.03 222.28 183.89 92.62 117.47
3-mo persistent AE probabilities (%)
Symptomatic ulcer [33] 0.04z 0.09 0.28 0.04z 0.04z 0.04z 0.04z 0.04z
Complicated GI bleed [33] 0.02z 0.05 0.07 0.02z 0.02z 0.02z 0.02z 0.02z
Myocardial infarction [33] 0.06z 0.15 0.06 0.06z 0.06z 0.06z 0.06z 0.06z
Stroke [33] 0.03z 0.03 0.08 0.03z 0.03z 0.03z 0.03z 0.03z
Heart failure [33] 0.01z 0.04 0.09 0.01z 0.01z 0.01z 0.01z 0.01z
Fracture 0.40 [34] 0.40 [35] 0.45 [35] 0.66 [36] 0.59( 0.59 [35] 0.89# 0.89 [35]
3-mo transient AE probabilities (%)
Dyspepsia 7.52z [33] 12.45 [33] 14.96 [33] 7.52z [33] 7.52z [33] 7.52z [33] 7.52z [33] 7.52z [33]
Nausea 8.30 2.80 5.00 7.90 [37] 37.20( 37.20 21.00 [38] 19.10
Diarrhea 5.70 4.40 4.10 3.90 [37] 5.90( 5.90 0.50 [38] 6.10
Constipation 7.60 1.80 3.30 5.30 [37] 38.20( 38.20 17.00 [38] 15.10
Insomnia 3.70 2.30 1.10 1.10yy 7.30( 7.30 4.00 [38] 7.30
Pruritus 0.60 1.80 2.10 0.60yy 13.70( 13.70 5.00 [38] 8.60
Vomiting 0.30 1.30 0.70 3.90 [37] 17.10( 17.10 8.00 [38] 6.90
Dizziness 5.40 1.70 1.30 35.50 [37] 20.7( 20.7 17.00 [38] 15.20
Somnolence 4.00 0.30 0.30 19.70 [37] 21.30( 21.30 12.00 [38] 9.40
Opioid abuse 0.00 0.00 0.00 0.00 3.34( 3.34 [39] 3.34 [38] 0.04
Relative risk with PPI usage
Symptomatic ulcer 0.4999 [40] 0.25 [33] 0.37 [33] 0.4999 [40] 0.4999 [40] 0.4999 [40] 0.4999 [40] 0.4999 [40]
Complicated GI bleed 0.4999 [40] 0.25 [33] 0.46 [33] 0.4999 [40] 0.4999 [40] 0.4999 [40] 0.4999 [40] 0.4999 [40]
Dyspepsia 0.4999 [40] 0.25 [33] 0.43 [33] 0.4999 [40] 0.4999 [40] 0.4999 [40] 0.4999 [40] 0.4999 [40]
AE, adverse event; APAP, acetaminophen; BID, twice a day; CLBP, chronic low back pain; discon, discontinuation; ER, extended release; GI, gastrointestinal; IR, immediate release; OA,
osteoarthritis; PDT, postdiscontinuation therapy; PPI, proton pump inhibitor; QD, once a day; Q6h, every 6 hours; RCT, randomized controlled trial.
 Meta-analysis of CLBP RCTs.
y Assumed the same as duloxetine.
( Assumed the same as oxycodone.
y Meta-analysis of OA RCTs.
99 Expert opinion.
z Assumed the same as no treatment.
# Assumed the same as tramadol.
 Meta-analysis of OA RCTs.
yy Assumed the same as the lowest comparator.
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Fig. 1 – Health state transition diagram (simplified).
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 3 4 – 3 4 4 337[22,23] and from CLBP RCTs for duloxetine. Discontinuation in
subsequent cycles was based on the initial rate of discontinua-
tion and expert opinion.Utilities
Treatment utilities were based on a meta-analysis and indirect
comparison of pain scores in CLBP RCTs using the DerSimonion-
Laird and Bucher methods [70–72]. Similar to the AE meta-
analysis, searches were performed for English-language RCTs of
21 possible CLBP oral comparators. A 12-week minimum duration
of treatment was among the inclusion criteria. RCTs were
required to report baseline pain and change from baseline pain
scores on a 1 to 10 or 1 to 100 scale. The outcome of interest was
the difference in change from baseline scores between treatment
and control arms.
Pain scores were converted to utilities by using a transfer-to-
utility (TTU) [73–77] regression equation developed from patient-
level pain and US preference-weighted EuroQol five-dimensional
(EQ-5D) questionnaire scores of three duloxetine RCTs in CLBP
[15–17]. Patient-level data from three Eli Lilly and Company
duloxetine CLBP placebo-controlled trials were used in the
analysis (ClinicalTrials.gov IDs NCT00767806, NCT00424593, andTable 2 – Persistent AE characteristics.
Ad
Symptomatic
ulcer
Complicated GI
bleed
M
in
Cost (3 mo) ($)
During 1,868 [33,41,42] 10,403 [41,42] 29,
Post 252 [41,42] 238 [42]
Utility weight
During 0.550 [51] 0.460 [51] 0.
Post 0.978 [33] 0.978 [33] 0.
Excess mortality (3 mo) (%)
During 0.00 [33] 4.30 [51] 16
Post 0.00 [33] 1.107 [51] 4
Age-related relative risk
o65 y 1.00 [33] 1.00 [33] 1
65 y þ 2.93 [57] 2.93 [57] 2
AE, adverse event; GI, gastrointestinal.NCT00408876). Data from NCT00767806 and NCT00408876 were
used to build the regression model, while data from NCT00424593
were used for validation.
The dependent variable was the last observed US EQ-5D
questionnaire health index score or its transformation. The
independent variables were the Brief Pain Inventory (BPI) 24-
hour average pain score at the same observation as well as other
potentially influencing variables such as sex and age. Histograms
were plotted to assess normality of the variables. Transforma-
tions were attempted to improve normality and were assessed by
skewness, kurtosis, and visual inspections of histograms and
residuals plots. Variables and their transformations were con-
sidered for inclusion by using stepwise selection. Those that were
statistically significant at P less than 0.10 were considered as
possible elements in the model. Goodness of fit was judged by the
adjusted coefficient of determination (R2), root mean square error
(RMSE), and Akaike information criterion values.
Population utility weights by age and sex for the United States
were taken from the National Health Measurement Study [78],
while utility weights for AEs were derived from the literature
[33,52,59,61,79].Costs
Drug costs were calculated using dosing consistent with clinical
trials and labeling. Average 2011 wholesale prices [29] were dis-
counted 16%, consistent with current actual wholesale acquisition
costs [80]. Opioid costs were adjusted in the first cycle of treatment
to reflect titration and upon discontinuation to reflect tapering
according to a Washington State Medicaid tapering calculator [30].
Titration schedules for duloxetine and pregabalin were found in the
literature [15,16,23]. Titration and discontinuation-related medical
service utilization was provided by expert opinion and priced by
using Medicare reimbursement rates adjusted by using a Medicare/
private payer cost ratio [31,32]. Costs for persistent during-AE health
states were determined by using the Healthcare Cost and Utiliza-
tion Project database of the Agency for Healthcare Research and
Quality [43], International Classification of Diseases, Ninth Revision,
codes from the Agency for Healthcare Research and Quality
Inpatient Quality Indicators Program [44], and the literature
[41,42,46–50]. Costs for persistent post-AE health states were taken
from the literature [41,42,46–50]. When necessary, costs were
inflated to 2011 US dollars by using the medical services component
of the US Consumer Price Index [81].verse event
yocardial
farction
Stroke Heart
failure
Fracture
345 [43,44] 19,109 [43,44] 11,006 [43,45] 5,044 [46,47]
750 [48] 616 [49] 1,867 [50] 247 [46,47]
370 [33] 0.350 [33] 0.710 [33] 0.880 [46,52]
878 [33] 0.708 [33] 0.998 [33] 0.952 [46,52]
.15 [53] 15.80 [54] 7.48 [55] 0.210 [46,56]
.32 [53] 1.69 [54] 2.61 [55] 0.025 [46]
.00 [33] 1.00 [33] 1.00 [33] 1.00 [46]
.45 [58] 2.45 [58] 2.45 [58] 1.61 [46]
Table 3 – Transient AE characteristics.
Event
cost ($)
3-mo
costs ($)
Cost of physician
visit ($) [31]
Utility weight
during event
Days of
treatment
Duration-
adjusted cost ($)
Dyspepsia 28 49 [41,42] 76 0.730 [33] 27.8 119
Nausea 0 6y [29] 76 0.887 [59] 12.5 77
Diarrhea 0 6y [29] 76 0.900 [59] 18.6 77
Constipation 539 [60] 66y [29] 76 0.888 [59] 39.1 720
Insomnia 0 282y [29] 76 0.887 [59] 34.5 259
Pruritus 0 47y [29] 76 0.958 [59] 31.8 169
Vomiting 0 6y [29] 76 0.887 [59] 3.8 76
Dizziness 0 0 76 0.887 [59] 15.5 76
Somnolence 0 0 76 0.887 [59] 28.8 76
Opioid abuse 5471 [60] NA NA 0.800 [61] 91.0 5471
AE, adverse event; NA, not applicable.
 Expert opinion.
y Treatment and dosing from Lilly September 8, 2011.
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The model enabled one-way and probabilistic sensitivity analyses
on 22 and 17 variables of interest, respectively, between dulox-
etine and any other comparator. Outputs are a tornado diagram
for one-way analysis and a scatter plot of incremental costs
versus quality-adjusted life-years (QALYs) as well as a cost-
effectiveness acceptability curve from probabilistic analysis.
Variables chosen for sensitivity analysis were those for which
there was substantial uncertainty, expectation of sensitivity, or
recommendation by an advisory body.Results
CLBP Efficacy Meta-Analysis
A systematic literature review of CLBP RCTs identified 16 clinical
trials for inclusion in a meta-analysis of efficacy of oral post–first-
line treatments in CLBP. The number of treatment arms found in
placebo-controlled trials was four for duloxetine, two each for
etoricoxib, oxycodone, oxymorphone, and tramadol/APAP, and one
for tapentadol. In oxycodone-controlled trials, there were two for
tapentadol, one for naproxen, and one for hydromorphone. No
RCTs were found for celecoxib, pregabalin, tramadol, or oxyco-
done/APAP. Our methods estimated the greatest improvement in
pain scores for those taking NSAIDs, followed by opioids and
duloxetine. Celecoxib and naproxen were assumed to have the
same efficacy as the pooled efficacy of etoricoxib and naproxen.
Equivalent efficacies were also assumed for tramadol and trama-
dol/APAP as well as for oxycodone/APAP and oxycodone. Pregaba-
lin was assumed to have the same efficacy as the placebo effect
seen in placebo arms of other RCTs. The only known RCTs of
pregabalin in CLBP are two phase 2 trials of unknown duration
described in an abstract that reports no statistically significant
difference between treatment and placebo [21].
TTU Regression
A regression model with only the untransformed pain score
predicting EQ-5D score produced an adjusted R2 of 0.3290.
Transformations and additional variables provided marginal
improvements, and so the single independent variable model
was chosen with the equation:
EQ-5D¼0:928590:04007 BPI
During validation, the Pearson correlation coefficient of the
predicted versus actual EQ-5D scores was 0.5181.Model Base-Case Results
The meta-analysis of CLBP RCTs and TTU conversion produced
the highest utilities for NSAIDs, followed by opioids, duloxetine,
and pregabalin. This was consistent with Kuijpers et al’s [10] 2011
systematic review, which found evidence of efficacy for NSAIDs
and opioids, but not for antidepressants. (Duloxetine and prega-
balin were not included in the Kuijpers review.)
The cost-effectiveness model estimated that when AEs were
considered, duloxetine became the most effective treatment, with
the highest number of QALYs, as seen in Table 4. Naproxen, as the
least expensive treatment, also appears on the cost-effectiveness
horizon in Figure 2. All other treatments were dominated. The
incremental cost-effectiveness ratio (ICER) for duloxetine over
naproxen was estimated to be $59,473 per QALY. Subgroup analyses
were performed (not shown) for a cohort aged 65 years and a cohort
at higher risk of CV and GI AEs. The model estimated ICERs for
duloxetine for these subgroups of $28,322 and $33,105, respectively.
Sensitivity Analyses
The output of a series of one-way sensitivity analyses is dis-
played as a tornado diagram. Figure 3 illustrates the results of
analyses with duloxetine and naproxen as comparators, with
ICERs for duloxetine. The probabilities of CV AEs associated with
NSAIDs are the most sensitive inputs in the analysis. The values
of these inputs are from the NICE model and were derived by
NICE from the large landmark trials Celecoxib Long-term Arthri-
tis Safety Study, Multinational Etoricoxib and Diclofenac Arthritis
Long-term programme, and Therapeutic Arthritis Research and
Gastrointestinal Event Trial [82–85]. The second most sensitive
input is the discount rate, which in the base case (3%) is the
recommended rate for US CEAs [86]. The next most sensitive
input is the price of duloxetine. The fourth most sensitive set of
inputs, the probabilities of GI AEs associated with NSAIDs, was
also obtained directly from the NICE model.
A substantial amount of uncertainty surrounds the utilities of
duloxetine and naproxen due to the small number of RCTs in our
meta-analysis and the TTU method of calculating them. The
utility for naproxen is especially uncertain because it is based
chiefly on etoricoxib RCTs. However, our methods assigned
NSAIDs the highest estimated utilities. It is more likely that this
utility is too high rather than too low. Reducing the utility for
naproxen by 0.005 lowers the ICER to $52,080. Assuming that
naproxen and duloxetine have equal efficacy reduces it further to
$42,283. Exchanging the pain score–based utilities to an alternate
set based on Roland Morris Disability Questionnaire scores,
however, has nearly no effect.
Table 4 – Base-case incremental results.
Treatment Total cost ($) QALYsy Life yearsy Incremental cost ($) Incremental QALYsy ICER
Tapentadol ER 54,559 12.2029 17.3682 Dominated
Oxycodone ER 52,820 12.1974 17.3644 Dominated
Oxycodone/APAP 51,834 12.1973 17.3654 Dominated
Duloxetine 51,450 12.2123 17.3682 1,333 0.0224 $59,473
Pregabalin 51,338 12.1884 17.3696 Dominated
Tramadol IR 51,218 12.2043 17.3675 Dominated (extended)
Celecoxib 50,438 12.1887 17.3166 Dominated
Naproxen 50,117 12.1899 17.3252
APAP, acetaminophen; ER, extended release; ICER, incremental cost-effectiveness ratio; IR, immediate release; QALYs, quality-adjusted life-
years.
 Costs discounted at 3%.
y Life years and QALYs discounted at 3%.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 3 4 – 3 4 4 339An incremental cost versus QALY scatter plot and a cost-
effectiveness acceptability curve are common outputs of prob-
abilistic sensitivity analysis. Figure 4 shows these outputs for
a comparison of duloxetine versus naproxen. The scatter plot
depicts the incremental costs versus QALYs from a 1000 iterations
of randomly selected inputs. A diagonal line across the plot
represents a $50,000 threshold. The large central point indicates
the mean of the incremental costs and QALYs. Placement slightly
above the line is consistent with base-case results. The accept-
ability curve shows a nearly linear increase with the graph
reaching 50% at approximately $60,000 and 82% at $70,000,
consistent with base-case results. Figure 5 shows the outputs
from an analysis comparing duloxetine to tramadol. In this case,
almost all points in the scatter plot appear below the $50,000
threshold. The acceptability curve found 56.7% and 94.9% prob-
abilities that the ICER was less than $30,000 and $40,000 per QALY,
respectively, and 99.7% samples preferred duloxetine if the will-
ingness to pay was $50,000. An analysis comparing duloxetine to
oxycodone/APAP, the least expensive strong opioid, estimated a
99.9% probability that duloxetine dominated oxycodone/APAP.Discussion
No previous CEAs of oral medications in CLBP were identified.
Therefore, a NICE model in OA was extended for cost-effectivenessFig. 2 – Cost-effectiveness plane with naproxen and duloxetine o
extended release; QALY, quality-adjusted life-year.evaluation in CLBP. Characteristics of the model that made it
adaptable to this setting include a utility structure that takes into
account treatment efficacy, general population HRQoL, and the
effects of AEs. The accommodation of AEs includes those that have
long-term effects on health and cost, as well as those that resolve
upon the discontinuation of treatment.
Our model compares duloxetine to several commonly used
oral treatments. Treatment-specific utilities were developed by
using a meta-analysis of the RCTs available and the TTU
technique. Where possible, data from the NICE economic model,
such as the probabilities of persistent CV and GI AEs, were used.
A novel maximum likelihood simulation method was used to
estimate transient AE probabilities. This was done to overcome
the common practice in the literature of reporting only those AEs
that occur more frequently than an arbitrary reporting threshold.
The model predicts duloxetine to be the most effective treatment
for CLBP (most QALYs) and to be cost-effective when compared
with all treatments other than generic NSAIDs. This information
may be valuable to US payers and health care policymakers as
well as patients and physicians when considering post–first-line
pharmacological treatment options. Although a generic NSAID
was included in the model (naproxen), its availability as an over-
the-counter treatment may place it outside the scope of the US
private payer perspective. In a scenario in which NSAIDs are
inappropriate or no longer effective, duloxetine dominates strong
opioids and is more effective than all other treatments.n the cost-effectiveness horizon. APAP, acetaminophen; ER,
Fig. 3 – Tornado diagram of one-way sensitivity analyses. AE, adverse event; CV, cardiovascular; GI, gastrointestinal; ICER,
incremental cost-effectiveness ratio; NSAID, nonsteroidal anti-inflammatory drug; PDT, postdiscontinuation therapy; PPI,
proton pump inhibitor; RMDQ, Roland Morris Disability Questionnaire; RR, relative risk; TAE, transient adverse event.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 3 4 – 3 4 4340Our analysis has a number of limitations. First, CLBP has not
been defined consistently. For the purposes of this model, we
have adopted a definition based on the criteria used in theFig. 4 – Probabilistic sensitivity analysis of duloxetine versus n
quality-adjusted life-year.clinical trials for which we had data: duration of at least 3
months and the presence of pain on most days. Second, the
evidence base for oral medications in CLBP is weak. Although ouraproxen. ICER, incremental cost-effectiveness ratio; QALY,
Fig. 5 – Probabilistic sensitivity analysis of duloxetine versus tramadol. ICER, incremental cost-effectiveness ratio; QALY,
quality-adjusted life-year.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 3 4 – 3 4 4 341comparators are commonly used CLBP treatments, searches
found no CLBP RCTs for four comparators and only four RCTs
were head-to-head. We have assumed efficacies for naproxen
and celecoxib to be equal to those for etoricoxib, for tramadol to
be equal to those for tramadol/APAP, and for oxycodone/APAP to
be equal to that for oxycodone. We have assumed that immediate
and extended release formulations have similar efficacy. We have
also assumed that AE rates for oral treatments are similar across
musculoskeletal pain conditions when given at similar doses.
Only the duloxetine AE rates are based on RCTs in CLBP. Ideally,
long-term studies would be available for such a chronic condi-
tion. None were found.
A relative wealth of information is available for duloxetine:
three high-quality CLBP RCTs, as well as a 41-week open label
extension trial. Our meta-analysis found as many RCTs only for
oxycodone and tapentadol, and most of these RCTs were not
placebo controlled.
There is inadequate comparative information from clinical
practice settings to confirm the findings of this model. A retro-
spective study of patients with CLBP in a privately insured claims
database found that patients initiating duloxetine experienced
similar costs for medical services and prescription drugs as
matched patients initiating other pharmacological agents or
noninvasive medical treatments. Analysis of a subset of patients
employed in companies providing disability claims found that
duloxetine-treated patients were associated with significantly
lower costs for medical services, while drug costs were similar
between the two groups [87]. Future research on the comparativecosts of medical services related to medication titration, discon-
tinuation, and the management of AEs in the care of patients
with CLBP would provide further insight on the findings of
this model.
A major assumption of the model is that patients receive
medication every day. This would not be the case in acute or
recurring LBP, and one could argue that it is unlikely in CLBP as
well. However, duloxetine is intended for the management of
chronic musculoskeletal pain of at least moderate severity. Most
RCTs of comparators required a baseline pain score of at least
4 (moderate pain) on a 10-point scale. Moreover, duloxetine is
intended to be taken daily and the RCTs on which the model is
based included daily treatment, regardless of comparator.
The use of the TTU technique instead of utility scores
produced by standard gamble or time trade-off methods may
be criticized. However, TTU regression is being used frequently in
illnesses as diverse as sleep dysfunction, OA, stroke, and bariatric
surgery [73,74,88–90]. The regression model achieved an adjusted
R2 of 0.329 with an RMSE of 0.134. Validation showed that it
tended to overestimate low utilities and underestimate higher
utilities with a Pearson correlation coefficient of 0.5181. In
comparison, Barton et al. [73] reports a preferred model for OA
of five variables achieving an R2 of 0.313 and an RMSE of 0.180.
Grootendorst et al. [74] likewise developed a regression model for
transferring Western Ontario and McMaster Universities Arthritis
Index scores to Health Utilities Index Mark 3 utilities using 15
variables; it explained approximately 40% of the variance with an
RMSE of 0.2065. The Grootendorst model was subsequently
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 3 4 – 3 4 4342validated by Marshall et al. [91] on two sets of trial data that
yielded RMSEs of 0.2066 and 0.1684 . Marshall et al. [91] confirmed
that predictive error was smaller with groups than with indivi-
dual patients, with the error decreasing as the group size
increased. Our BPI to EQ-5D regression equation explained as
much variance as the Barton et al. model though somewhat less
than the Grootendorst et al. model, yet yielded a smaller RMSE
than either of them while using a much simpler model.
The additional AEs in our model that did not appear in the
earlier NICE model are those that occur at substantially different
rates among the comparators. Among these, AEs such as frac-
ture, opioid abuse, and constipation are significant factors in the
model. Other AEs such as nausea or somnolence are more likely
to lead to discontinuation if not tolerated and therefore have little
economic impact.
A number of plausible AEs and costs that would have
benefited the cost-effectiveness of duloxetine were omitted. For
example, epidemiological evidence has associated renal failure
with the use of nonselective NSAIDs [92–96]. Very recently, two
studies linked proton pump inhibitors to increased fracture and
CV risks [97,98]. A large recent study associated significantly
higher mortality with opioid misuse [99]. Costs have not been
included for the management of long-term issues associated
with opioid treatment, such as dose management. The effects of
including these AEs and costs would be to reduce the QALYs and
increase the costs of NSAID and opioid treatments, improving the
relative cost-effectiveness of remaining comparators, including
duloxetine.
Potentially serious AEs such as bleeding, hepatoxicity, and
suicidality have been associated with the use of duloxetine or
drugs in its class, and precautions or warnings for these AEs are
found in the Food and Drug Administration package insert. The
use of duloxetine in adult patients is not known to be associated
with risk to a degree likely to produce economically relevant
consequences, and quantifying the potential impact of additional
AEs was not feasible from the limited description of these events
in the published literature [19,100–104].
A final limitation may be that we modeled opioid dependency
as a transient AE despite evidence that opioid dependency may
confer long-term economic and HRQoL impacts as well as excess
mortality. Modeling opioid dependency as a persistent AE would
further disadvantage strong opioids, which are already dominated.Conclusions
Duloxetine offers an additional option for a condition for which
no existing treatments have high-quality evidence of substantial
benefit. Duloxetine has a different safety profile from existing
treatments, which may make it a viable alternative for popula-
tions at high risk for some of the serious AEs associated with
current therapies. This model estimated that duloxetine is a cost-
effective post–first-line treatment for CLBP compared with all but
generic NSAIDs. Therefore, duloxetine may offer a cost-effective
alternative to current options for the management of CLBP.
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